Literature DB >> 15856265

Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis.

Stefan Farkas1, Matthias Hornung, Christine Sattler, Karoline Edtinger, Markus Steinbauer, Matthias Anthuber, Hans J Schlitt, Hans Herfarth, Edward K Geissler.   

Abstract

BACKGROUND: Leukocyte recruitment to sites of intestinal inflammation is a crucial multi-step process, leading ultimately to the accumulation of cells in the inflamed tissue. These interactions in the gut are critically dependent on the mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is expressed on endothelial cells within the mesenteric lymph nodes and the lamina propria of the intestine. Here, we investigate the pathophysiologic role of MAdCAM-1 in the intestinal microcirculation in vivo.
METHODS: Using a standard mouse model, chronic colitis was established after four cycles of dextran sodium sulfate (DSS) application. MAdCAM-1 expression was investigated by immunohistochemistry and Western blotting, as well as real-time polymerase chain reaction (PCR). Intravital microscopy was used to study the role of MAdCAM-1 on leukocyte-endothelium interactions and leukocyte extravasation.
RESULTS: Significant changes in MAdCAM-1 were observed in mice with chronic DSS-induced colitis. Upregulation of MAdCAM-1 expression in chronic colitis was demonstrated on a protein and messenger ribonucleic acid (mRNA) level. Anti-MAdCAM-1 treatment lead to a marked reduction (>60%) of leukocyte sticking and extravasation in vivo, compared to the controls. This was parallelled by a significant reduction (45%) of intestinal inflammation, as measured by the histologic grading score.
CONCLUSION: These in vivo results demonstrate a distinct role of MAdCAM-1 in inflammatory intestinal diseases, and suggest that therapeutic strategies targeting this adhesion molecule could be useful in the treatment of chronic colitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856265     DOI: 10.1007/s00384-004-0709-y

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  35 in total

1.  Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1.

Authors:  S Kato; R Hokari; K Matsuzaki; A Iwai; A Kawaguchi; S Nagao; T Miyahara; K Itoh; H Ishii; S Miura
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

2.  An improved intravital microscopy system.

Authors:  A G Harris; R Hecht; F Peer; D Nolte; K Messmer
Journal:  Int J Microcirc Clin Exp       Date:  1997 Nov-Dec

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease.

Authors:  S Wirtz; M F Neurath
Journal:  Int J Colorectal Dis       Date:  2000-06       Impact factor: 2.571

5.  The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.

Authors:  Makoto Sasaki; Sulaiman Bharwani; Paul Jordan; Takashi Joh; Kenneth Manas; April Warren; Hirohisa Harada; Patsy Carter; John W Elrod; Michael Wolcott; Matthew B Grisham; J Steven Alexander
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

Review 6.  Antiadhesion molecule therapy in inflammatory bowel disease.

Authors:  Gert van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2002-07       Impact factor: 5.325

7.  Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides.

Authors:  Ann-Kristin Spiik; Anna Ridderstad; Lars-Göran Axelsson; Tore Midtvedt; Lars Björk; Sven Pettersson
Journal:  Int J Colorectal Dis       Date:  2002-02-20       Impact factor: 2.571

8.  Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis.

Authors:  Kathleen J Myers; Sreekant Murthy; Anne Flanigan; Donna R Witchell; Madeline Butler; Susan Murray; Andrew Siwkowski; Deborah Goodfellow; Karen Madsen; Brenda Baker
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

9.  Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis.

Authors:  F Obermeier; N Dunger; U G Strauch; N Grunwald; H Herfarth; J Schölmerich; W Falk
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

10.  The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules.

Authors:  R A Warnock; J J Campbell; M E Dorf; A Matsuzawa; L M McEvoy; E C Butcher
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  20 in total

1.  Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration.

Authors:  Amir J Guri; Raquel Hontecillas; Josep Bassaganya-Riera
Journal:  Clin Nutr       Date:  2010-03-16       Impact factor: 7.324

2.  Anti-adhesion molecule therapy for inflammatory bowel disease.

Authors:  Subrata Ghosh; Remo Panaccione
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

3.  Role of blood- and tissue-associated inducible nitric-oxide synthase in colonic inflammation.

Authors:  Christian F Krieglstein; Christoph Anthoni; Wolfgang H Cerwinka; Karen Y Stokes; Janice Russell; Matthew B Grisham; D Neil Granger
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 4.  Leukocyte adhesion molecules in animal models of inflammatory bowel disease.

Authors:  Jesús Rivera-Nieves; Gezahegn Gorfu; Klaus Ley
Journal:  Inflamm Bowel Dis       Date:  2008-12       Impact factor: 5.325

Review 5.  A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.

Authors:  Kenechukwu O Chudy-Onwugaje; Kaci E Christian; Francis A Farraye; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

6.  Impact of adrenomedullin on dextran sulfate sodium-induced inflammatory colitis in mice: insights from in vitro and in vivo experimental studies.

Authors:  Yoshiaki Hayashi; Kenta Narumi; Shigetsugu Tsuji; Toshinari Tsubokawa; Masa-aki Nakaya; Tomohiko Wakayama; Masahiko Zuka; Tohru Ohshima; Masakazu Yamagishi; Toshihide Okada
Journal:  Int J Colorectal Dis       Date:  2011-06-15       Impact factor: 2.571

7.  Targeting improves MSC treatment of inflammatory bowel disease.

Authors:  In Kap Ko; Byung-Gyu Kim; Amad Awadallah; Jenifer Mikulan; Paul Lin; John J Letterio; James E Dennis
Journal:  Mol Ther       Date:  2010-04-13       Impact factor: 11.454

8.  Skin- and gut-homing molecules on human circulating γδ T cells and their dysregulation in inflammatory bowel disease.

Authors:  E R Mann; N E McCarthy; S T C Peake; A N Milestone; H O Al-Hassi; D Bernardo; C T Tee; J Landy; M C Pitcher; S A Cochrane; A L Hart; A J Stagg; S C Knight
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

9.  Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis.

Authors:  Eric Hyun; Patricia Andrade-Gordon; Martin Steinhoff; Paul L Beck; Nathalie Vergnolle
Journal:  Inflamm Res       Date:  2010-03-26       Impact factor: 4.575

Review 10.  Advances in sexually transmitted infections of the gastrointestinal tract.

Authors:  Siew C Ng; Brian Gazzard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-25       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.